InGeneron Publishes Overview on Current State and Potential of Regenerative Cell Therapy in Orthopedics
Retrieved on:
Monday, January 24, 2022
Stem Cells, Biotechnology, Physical Therapy, FDA, Health, Pharmaceutical, Research, Hospitals, Surgery, Science, Clinical Trials, Stem cell, Patient, Technology, Orthopedic surgery, Journal, B cell, RT, Journal of Orthopaedic Surgery and Research, M.A, Adipose tissue, Fibroblast, Pericyte, New Orleans, Lists of diseases, Regeneration, Department, Review, Microdeletion syndrome, Ludwig Maximilian University of Munich, Lundeen, Tulane University, FDA, Cell, Physician, Endothelium, Furia, Pharmaceutical industry, Fine chemical, Medical device, Research, InGeneron, Political movement, the Transpose® RT System and Current Clinical Trials, InGeneron, THE TRANSPOSE® RT SYSTEM AND CURRENT CLINICAL TRIALS, INGENERON
InGeneron, Inc., a clinical stage biotechnology company, announced the publication of a succinct scientific review of regenerative cell therapy, commonly called stem cell therapy, to treat orthopedic indications.
Key Points:
- InGeneron, Inc., a clinical stage biotechnology company, announced the publication of a succinct scientific review of regenerative cell therapy, commonly called stem cell therapy, to treat orthopedic indications.
- The publication provides an approachable overview of stem cell biology and clarifies common misconceptions about adipose-derived regenerative cells (ADRCs) including vascular-associated pluripotent stem cells (vaPS cells).
- Summarizing 20 years of both basic and clinical research, the review aims to provide a straightforward look at the current state of orthopedic regenerative cell therapies and clarifies the role of different regenerative cells, such as vaPS cells, in tissue regeneration.
- InGenerons Transpose RT cell therapy platform consists of a processing unit, a set of disposables, and Matrase, a proprietary enzyme mixture.